The Trump administration has been barred from carrying out its sweeping plan to restructure and downsize the Department of ...

Kura Oncology said one-quarter of patients with certain forms of advanced acute myeloid leukemia went into complete remission ...

President Donald Trump unofficially asked CMS Administrator Mehmet Oz to lead the administration’s talks with drugmakers to ...

Volastra reports promising Phase 1/2 data for VLS-1488 in solid tumors, with good safety and early efficacy signals in ...

Gilead's Trodelvy shows significant improvement in progression-free survival for metastatic triple-negative breast cancer ...

Geoffrey Porges, a longtime biotech analyst and well-known Wall Street figure, stepped down as CFO of the New York biotech ...

Sanofi will acquire Vigil for its oral small molecule TREM2 project, dubbed VG-3927, that is on tap for a Phase 2 in ...

Merus completed its rollout of Phase 2 head and neck cancer data on Thursday, touting overall survival results that at least ...

FDA Commissioner Marty Makary defended thousands of staff cuts during his first congressional hearing since taking office, ...

Cigna on Wednesday said it negotiated with Novo Nordisk and Eli Lilly to secure deeper GLP-1 drug discounts for employers ...

Beam Therapeutics CEO John Evans warns against AI hype in drug development, drawing parallels to past CRISPR expectations, ...

Hinge Health prices IPO at $32/share, valuing company at $3B. CEO Daniel Perez's firm to trade as HNGE on NYSE, raising ...